Composite biomarker for cancer therapy
Targeted administration of an anti-PD-1 antagonist and IDO1 inhibitor based on a specific biomarker profile improves treatment outcomes for bladder cancer and squamous cell carcinoma by enhancing efficacy and survival rates.
AU2020353079B2Pending Publication Date: 2026-07-09BRISTOL MYERS SQUIBB CO
0 Cites 0 Cited by
Patent Information
- Application Number
- AU2020353079
- Authority / Receiving Office
- AU · AU
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2019-09-25
- Filing Date
- 2020-09-24
- Publication Date
- 2026-07-09
- Estimated Expiration
- 2040-09-24
AI Technical Summary
Technical Problem
Existing cancer immunotherapies, such as those using PD-1 inhibitors, vary in effectiveness due to unique patient characteristics, necessitating targeted therapeutic strategies to identify patients likely to respond positively.
Method used
Administering an anti-PD-1 antagonist and an indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor to patients with a high IFNy inflammatory signature score and low tryptophan 2,3-dioxygenase 2 (TDO2) gene expression score, identified through a specific gene panel analysis.
Benefits of technology
Enhances treatment efficacy for bladder cancer and squamous cell carcinoma of the head and neck by reducing cancer burden and improving progression-free and overall survival probabilities.
✦ Generated by Eureka AI based on patent content.
Abstract
The disclosure provides a method for treating a subject afflicted with a cancer comprising administering to the subject a therapeutically effective amount of an anti-PD-1 antagonist, e.g., an anti-PD-1 or anti-PD-L1 antibody, in combination with an indoleamine 2,3-dioxygenase inhibitor, wherein the subject is identified as exhibiting a combined biomarker comprising (a) a high IFNγ inflammatory signature score and (b) a low tryptophan 2,3-dioxygenase 2 (TDO2) gene expression score. The high IFNγ inflammatory signature score is determined by measuring the expression of a panel of IFNγ related inflammatory genes in a cancer sample obtained from the subject, wherein the gene panel comprises, e.g., IFNγ, CXCL10, CXCL9, HLA-DRA, IDO1, and STAT1. In some aspects, the gene panel further comprises CCR5, CXCL11, GZMA, and PRF1. In some aspects, the gene panel comprises CXCR6, TIGIT, PD-L1, PD-L2, LAG3, NKG7, PSMB10, CMKLR1, CD8A, IDO1, CCL5, CXCL9, HLA.DQA1, CD276, HLA.DRB1, STAT1, HLA.E, and TDO2.
Need to check novelty before this filing date? Find Prior Art